Technology offer : Leptospirosis Diagnostic

Technology's description

Leptospirosis is a growing public health concern in many tropical and subtropical countries. However, its diagnosis is difficult because of non-specific symptoms and concurrent other endemic diseases. In many regions the laboratory diagnosis is not available due to a lack of preparedness and simple diagnostic assay or difficult access to references laboratories. The technology developed within the Pasteur Institute refers to the use of a new antigen for the detection of anti-leptospira human IgM. The technology has been developed in ELISA and Vertical flow rapid diagnostic test (RDT). First tries gives for ELISA a sensitivity of 94% and specificity of 99%, and the RDT shows a sensitivity of 90% and specificity of 94%. Domestic and farm animals are also very susceptible to leptospira bacteria. The technology could be easily developed for animal diagnosis.



Advantages

  • Field adapted  diagnostic
  • Few final products can be developed from this technology
  • Major public health concern in many regions
  • Pasteur Institute developing laboratory : National Reference Center for leptospirosis, and WHO Collaborating Center
  • Can be adapted to Animal health
  • Can be used as a differential diagnosis
Ref : OT-00006

Area of activity : HEALTH COSMETOLOGY

Download pdf

Industrial applications

  • ELISA kit, and Rapid Diagnostic Test, for humans and animals.

Intellectual property

  • Protect by a Patent

Technology transfer

  • Co-development with licensing agreement

CONTACT


Franck ADELINE
Business developer

franck.adeline@cvt-sud.fr
P: +33 (0) 491 999 456